Chronic Kidney Disease
Conditions
Keywords
Renal blood flow, Regional renal blood flow, MRI
Brief summary
Comparison of renal blood flow measurements by PAH clearance and MRI
Detailed description
The traditional measurement of renal blood flow in ml/min involves the collection of multiple blood and urine samples after an infusion of a drug called para-aminohippurate (PAH) is given. In this study, the investigators determine the ability of MRI to estimate renal blood flow. The primary hypothesis is that renal blood flow as measured by PAH clearance is similar to renal blood flow as estimated by MRI. The measurements by PAH clearance and MRI are both performed on the same day.
Interventions
DRUGFurosemide
Renal blood flow is measured after the administration of 20 mg of furosemide during MRI scan only.
OTHERPlacebo
Sponsors
Wake Forest University
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
In this study, the investigators will enroll 16 men and women aged ≥ 18 years with Stage II - V chronic kidney disease (CKD). In addition, the investigators will enroll 4 subjects with a glomerular filtration rate (GFR) of greater than 60 ml/min who do not have any evidence of CKD.
Exclusion criteria
This study excludes those not suitable for MRI or for the interventional pharmacologic procedures.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Measurement of Renal Blood Flow of the Kidney by the PAH Method | Renal blood flow is estimated over 1 hour by PAH | Renal blood flow is estimated by the PAH method. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Measurement of Regional Blood Oxygenation by MRI | One measure after furosemide (day 1) | Estimate of renal blood flow by using MRI scans before and after the administration of furosemide |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Furosemide With and without furosemide
Furosemide: Renal blood flow is measured before and after the administration of 20 mg of furosemide. | 10 |
| Total | 10 |
Baseline characteristics
| Characteristic | Furosemide |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 2 Participants |
| Age, Categorical Between 18 and 65 years | 8 Participants |
| Region of Enrollment United States | 10 participants |
| Sex: Female, Male Female | 6 Participants |
| Sex: Female, Male Male | 4 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 0 / 10 |
| serious Total, serious adverse events | 0 / 10 |
Outcome results
Primary
Measurement of Renal Blood Flow of the Kidney by the PAH Method
Renal blood flow is estimated by the PAH method.
Time frame: Renal blood flow is estimated over 1 hour by PAH
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Furosemide | Measurement of Renal Blood Flow of the Kidney by the PAH Method | 190 ml/min |
Secondary
Measurement of Regional Blood Oxygenation by MRI
Estimate of renal blood flow by using MRI scans before and after the administration of furosemide
Time frame: One measure after furosemide (day 1)
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Furosemide | Measurement of Regional Blood Oxygenation by MRI | 300 ml/min |